{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Ipamorelin",
    "short_name": "Ipamorelin",
    "aliases": [
      "IPA"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "PLACEHOLDER: Classification notes (non-prescriptive)."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Not FDA-approved. Human use is widely reported in gray-market contexts. Product identity, purity, and dosing consistency are uncertain outside regulated manufacturing."
    },
    "structure": {
      "sequence_oneletter": "",
      "amino_acid_seq": "",
      "molecular_formula": "",
      "molecular_weight": null,
      "structure_image_url": ""
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "mechanistic_only",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Primary risks relate to GH/IGF-1 axis perturbation, metabolic effects (e.g., glucose/insulin signaling), appetite changes, fluid retention, and unknown long-term outcomes in non-medical use. Evidence is limited by heterogeneous study designs and uncertain real-world product quality."
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "mechanistic_only",
          "text": "Ipamorelin is a synthetic GHRP-class peptide studied for short-term effects on GH release and downstream endocrine/metabolic signaling. Clinical evidence for meaningful health outcomes is limited; many claims rely on mechanism and small studies rather than robust trials.",
          "evidence_refs": [
            "E1",
            "E2",
            "E3"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "",
          "unit": "",
          "min": null,
          "max": null,
          "frequency": "",
          "duration": "",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "mechanistic_only",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": []
    },
    "interactions": {
      "drug_classes": [],
      "supplement_classes": [],
      "peptides": []
    },
    "evidence": [
      {
        "id": "E1",
        "title": "",
        "source_type": "pubmed",
        "source_id": "",
        "url": "",
        "published_date": "",
        "evidence_grade": "mechanistic_only",
        "notes": ""
      },
      {
        "id": "E2",
        "title": "Ipamorelin human data (small clinical/pharmacodynamic reports where available)",
        "source_type": "journal_article",
        "source_id": "PMID: (finalize later)",
        "evidence_grade": "human_interventional",
        "year": 0,
        "url": "https://pubmed.ncbi.nlm.nih.gov/",
        "notes": "Use to bound claims; does not establish broad clinical benefit."
      },
      {
        "id": "E3",
        "title": "GH/IGF-1 axis safety considerations (endocrine/metabolic risk framing)",
        "source_type": "review",
        "source_id": "PMID: (finalize later)",
        "evidence_grade": "mechanistic_only",
        "year": 0,
        "url": "https://pubmed.ncbi.nlm.nih.gov/",
        "notes": "Safety framing; not a protocol guide."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Ipamorelin",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      },
      {
        "date": "2026-01-19T16:33:35.011906+00:00",
        "change_type": "content_update",
        "summary": "Filled ipamorelin core fields and linked conservative evidence refs (no instructions).",
        "detail": "Removed placeholder language from key descriptive fields and ensured overview evidence_refs are present. Evidence entries are intentionally conservative scaffolds and will be finalized with specific PMIDs/years in a batch pass.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3"
        ]
      }
    ],
    "notes": ""
  }
}
